Navigation Links
Alexza and Grupo Ferrer Amend Adasuve™ Partnership
Date:3/7/2012

njections should be administered only in exceptional circumstances.

About Grupo Ferrer
Grupo Ferrer is a privately-held European R&D-based pharmaco-chemical and medical device company headquartered in Barcelona, Spain.  Founded in 1959, the group encompasses today 45 companies developing its activities in Europe, Latin America, Africa, Middle East, Asia and the United States.  In total, Grupo Ferrer's human healthcare products are being commercialized in 93 countries through 26 direct subsidiaries (including Joint Ventures) and 70 partners and distributors. 

Grupo Ferrer carries out activities throughout the full value-chain of the pharma business, from R&D to international marketing, including fine chemicals development and both raw material and pharmaceutical product manufacturing.  For this purpose, Grupo Ferrer has research centres in Spain and Germany, as well as manufacturing sites in Europe and Latin America.

Grupo Ferrer's regulatory expertise has resulted in more than 800 active registration dossiers worldwide, including high added-value products for orphan and life-threatening diseases.  The aim of Grupo Ferrer's corporate strategy is to establish alliances and long-term relationships with biotechnology and pharmaceutical companies within its strategic therapeutic areas.  The company holds a long track record of agreements signed with big multinationals, as well as with medium size pharmaceutical companies and small biotech or R&D-based companies.

The company has experience with high value-added products, for very specific indications (i.e., Remodulin® (Treprostinil) for PPH, Egrifta® (tesamorelin) for HIV lipodistrophy) that may have specific requirements in terms of administration (injectables, subcutaneous pumps, etc.). 

For more information about Grupo Ferrer, visit the Company's web site at www.ferrergrupo.com<
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alexza Announces Proposed Public Offering of Common Stock and Warrants
2. FDA Psychopharmacologic Drugs Advisory Committee Recommends Approval of Alexzas ADASUVE™
3. Alexza Presents Staccato® Loxapine Responder Analyses in Agitated Adult Patients with Schizophrenia or Bipolar Disease at the 2011 USPMHC Annual Conference
4. Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
5. Alexza Pharmaceuticals to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
6. Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
7. Alexza Announces the Adasuve™ (Staccato® Loxapine) PDAC Meeting Date of December 12, 2011
8. Alexza Pharmaceuticals to Present at the 18th Annual NewsMakers in the Biotech Industry Conference
9. Alexza and Grupo Ferrer Establish Partnership for the Commercialization of Adasuve™ (Staccato® Loxapine) in Europe and Latin America
10. Alexza Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
11. Alexza Announces Adasuve™ (Staccato® Loxapine) PDUFA Goal Date of February 4, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015 Alimera Sciences, Inc. (NASDAQ: ... that specializes in the research, development and commercialization ... for the fourth quarter and year ended December ... a pivotal year for Alimera Sciences, most notably ... September for the treatment of diabetic macular edema," ...
(Date:3/4/2015)... , March 4, 2015 Acsis Inc., ... and serialization solutions, announced it will be hosting a ... The live event, "How to Boost Manufacturing Efficiency and ... March 18th at 2:00 PM EDT.  ... Acsis, and John Gordon , Chief Information Officer ...
(Date:3/4/2015)... ROCHESTER, Minn. , March 4, 2015   ... reached an agreement to develop the next generation of ... "We are hoping that this technology will be ... obesity and diabetes," says James Levine, M.D., Ph.D. ... researcher. "They are accurate, inexpensive, and can be integrated ...
Breaking Medicine Technology:Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 2Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 3Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 4Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 5Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 6Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 7Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 8Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 9Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 10Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 11Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 12Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 13Alimera Sciences Reports Fourth Quarter and Full Year 2014 Financial Results 14Mayo Clinic and Gentag, Inc. Announce Agreement To Develop Wireless Sensors for Treatment of Obesity and Diabetes 2Mayo Clinic and Gentag, Inc. Announce Agreement To Develop Wireless Sensors for Treatment of Obesity and Diabetes 3
... HAYWARD, Calif., Aug. 11, 2011 While media worldwide ... of  food-borne bacterial epidemics, a new USDA study finds ... its toxins--at the center of many of today,s most ... ground-breaking research conducted at the Albany, California, Western Regional ...
... WILLOWICK, Ohio, Aug. 11, 2011 Time is money, and time ... throwing money away. A first-of-its-kind mobile and HTML5 app ... and medical professionals save both time and money. With just a ... to a list of the optimum ultrasound machines based on their ...
Cached Medicine Technology:Scientists at USDA Says CREAGRI HIDROX® Effective Against Staphylococcus aureus Bacteria and Staphylococcus Enterotoxin A 2Providian Medical Launches New Tool to Make Finding the Right Ultrasound Machine Easier Than Ever 2
(Date:3/4/2015)... The emergence of nanotechnology has ... past decade. The pharmaceutical world has witnessed advancements ... the form of liposomes and polymeric nanoparticles that ... safety and efficiency. In the area of ... upon the enhanced permeability and retention (EPR) effect ...
(Date:3/4/2015)... (PRWEB) March 05, 2015 The ... a value of $5,632.8 million by 2019, at ... of 2014 to 2019. , Browse through the ... analysis of industry trends and segments, with the ... , Phthalic Anhydride (PA) is a derivative ...
(Date:3/4/2015)... March 04, 2015 Dr. Christopher Asandra, ... Medical Center today lamented the FDA’s recent decision ... (TRT). He argued that FDA’s conclusions are not ... men who suffer from testosterone deficiency. , “The FDA ... on testosterone replacement therapy,” said Dr. Asandra. “There is ...
(Date:3/4/2015)... March 04, 2015 FDA’s New Inspection ... **FDAnews Webinar**, March 24, 2015 — 1:30 p.m. – ... generally know within four hours of an inspection whether ... is on their “good” list, they’ll merely ask for ... manufacturer is on the “bad” list, the manufacturer must ...
(Date:3/4/2015)... York, NY (PRWEB) March 04, 2015 ... creative, breakthrough marketing campaign called 'We Love Smokers' from ... cravings for tobacco. , "It’s important to establish ... be true to it. Our idea, 'We Love Smokers' ... leadership point of view. We created a bold tone ...
Breaking Medicine News(10 mins):Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 2Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 3Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 2Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 3Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 2Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 3
... to Iowa from Los Angeles; more ... shipments from Chicago planned, LOS ANGELES, ... Christian relief agency World Vision is dispatching an,initial truckload of emergency ... of affected families., "World Vision will be providing basic items ...
... complain that math homework won,t help them in real life, ... cancer. , In a recent study that combined math and ... (CML) may be cured of the disease with an optimally ... their own immune response. , In the June 20 edition ...
... to pulmonary arterial hypertension, study found , , THURSDAY, ... reduced clinical decline in patients with early-stage pulmonary ... is a progressive disease in which increased pulmonary ... the heart, eventually leading to heart failure and ...
... Pa., June 19 ADVERTISEMENT - The following,statement was ... Topaz &,Kessler, LLP:, Schiffrin Barroway Topaz & Kessler, ... In re Merck & Co. Inc. Securities, Derivative, &,ERISA ... Court for the,District of New Jersey. The Court recently ...
... Fix Competitive Bidding System for DMEPOS,Equipment, ALEXANDRIA, ... of the House Ways & Means Health Subcommittee, ... Reform,Act of 2008. Sens. Max Baucus (D-MT) and ... Senate Finance Committee, have introduced S.3144, the,companion bill. ...
... to Pennsylvania-Grown Tomatoes, HARRISBURG, Pa., June 19 ... been confirmed among Pennsylvania,residents, State Health Secretary Dr. ... to the current multi-state Salmonella outbreak,associated with tomatoes ... April., One case each has been identified ...
Cached Medicine News:Health News:World Vision Responding to Record Flooding in Midwest 2Health News:Math could help cure leukemia 2Health News:Math could help cure leukemia 3Health News:Drug Effective Against Heart-Lung Disorder 2Health News:Schiffrin Barroway Topaz & Kessler, LLP Announces Court Ruling Relating to Merck & Co. Inc.'s Employee Savings & Security Plan, the Merck & Co., Inc. Employee Stock Purchase & Savings Plan, and the Merck Puerto Rico Employee Savings & Security Plan 2Health News:Schiffrin Barroway Topaz & Kessler, LLP Announces Court Ruling Relating to Merck & Co. Inc.'s Employee Savings & Security Plan, the Merck & Co., Inc. Employee Stock Purchase & Savings Plan, and the Merck Puerto Rico Employee Savings & Security Plan 3Health News:NCPA Statement Endorsing H.R. 6252 and S.3144 2Health News:Pennsylvania Department of Health Confirms Fifth Salmonella Case Linked to National Outbreak 2
The Buffered Wright Stain is a single solution stain that contains the fixative, buffer, and stain for rapid and convenient staining of blood smears. It is packaged in a 32-oz. bottle for ease of use...
Our Wright stain is a dual-use stain for peripheral blood and bone marrow smears. It produces results similar to those of the Giemsa stain with a slightly greater contrast....
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
For the quantitative determination of Albumin in serum. Endpoint procedure with Amax at 630 nm. Linearity: to 6 g/dl. Liquid ready-to-use reagent....
Medicine Products: